Cost of goods sold

Pervasip Announces Third Quarter Financials

Retrieved on: 
Tuesday, October 17, 2023
Bank statement, PVSP, Cost of goods sold, Film industry

SEATTLE, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, and its wholly owned subsidiary, Artizen Corporation, today announced the filing of its unaudited financial statements for its 3rd Quarter ended August 31, 2023.

Key Points: 
  • SEATTLE, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, and its wholly owned subsidiary, Artizen Corporation, today announced the filing of its unaudited financial statements for its 3rd Quarter ended August 31, 2023.
  • 60% Gross Margin Improvement: Gross profits for the three months ended August 31, 2023, totaled $1,994,465 compared to $1,257,843 during the same period in 2022, an increase of almost 60%, leading to 2023 3rd quarter gross margins of 45%, compared to 29% for the 3rd quarter 2022.
  • The quarter-over-quarter comparison best reflects the results of the Company’s cultivation investments and process improvements.
  • Income from Operations increased by 1,131%: Operating income rose to $591,751 for the quarter ending August 31, 2023, compared to $52,312 for the same period ending August 31, 2022.

RETRANSMISSION: HIVE Digital Provides September 2023 Production Update and Purchase of 1,000 S19k Pro ASICs

Retrieved on: 
Friday, October 6, 2023
Mining, Investment, GPU, Cost of goods sold, Digital electronics, TSX, Acquisition, Calendar, Depreciation, ASIC, AI, MD, Bank statement, Administration, HIVE, General Administration of Press and Publication, G. Heileman Brewing Company, Weather, Miner, FSE, News, Executive, ROI, BTC, Cryptocurrency, Rare-earth element, Typesetting, Bitcoin, Application-specific integrated circuit

Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (the "Company" or "HIVE") is pleased to announce the unaudited production figures from the Company's global Bitcoin operations for the month of September 2023, with 269.5 Bitcoin produced in September. The Company has maintained over 3.83 Exahash ("EH/s") of Bitcoin mining capacity on average for September 2023, including ASIC and GPU BTC hashrate (all amounts in US dollars, unless otherwise indicated).

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (the "Company" or "HIVE") is pleased to announce the unaudited production figures from the Company's global Bitcoin operations for the month of September 2023, with 269.5 Bitcoin produced in September.
  • Our team's track record, couple with our fiscal prudence, puts us in a strong position to weather the halving event next April.
  • Our focus is to maximize ROI on Bitcoin mining ASICs we purchase now, by making strategic acquisitions of only the very best offers in the market."
  • Mr. Holmes, HIVE's Executive Chairman, added, "We're laser focused on acquiring high-efficiency Bitcoin mining rigs at the best possible price.

HIVE Digital Provides September 2023 Production Update and Purchase of 1,000 S19k Pro ASICs

Retrieved on: 
Friday, October 6, 2023
Mining, Investment, GPU, Cost of goods sold, Digital electronics, TSX, Acquisition, Calendar, Depreciation, ASIC, AI, MD, Bank statement, Administration, HIVE, General Administration of Press and Publication, G. Heileman Brewing Company, Weather, BTC, Miner, FSE, Executive, ROI, Cryptocurrency, Rare-earth element, Typesetting, Bitcoin, Application-specific integrated circuit

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated August 17, 2023, to its short form base shelf prospectus dated May 1, 2023.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (the "Company" or "HIVE") is pleased to announce the unaudited production figures from the Company's global Bitcoin operations for the month of September 2023, with 269.5 Bitcoin produced in September.
  • Our focus is to maximize ROI on Bitcoin mining ASICs we purchase now, by making strategic acquisitions of only the very best offers in the market."
  • The Company notes this variance in ROI is accounted for by purchase price and delivery date.
  • Mr. Holmes, HIVE's Executive Chairman, added, "We're laser focused on acquiring high-efficiency Bitcoin mining rigs at the best possible price.

MarketMan Announces Next Generation of Premium Features Using Predictive Analytics for Food Service COGS Management

Retrieved on: 
Saturday, May 20, 2023
Software, Restaurant, Bar, Supermarket, Data Management, Technology, Supply Chain Management, Food, Beverage, Retail, Software as a service, COGS, McCormick Place, Overalls, POS, Meal Ticket, Cost of goods sold, Cost, Algorithm, Food delivery, Online shopping

MarketMan , a comprehensive SaaS food service inventory and purchasing platform, today announced the launch of its next-generation premium features utilizing predictive analytics that provide restaurants with automated management of their cost of goods.

Key Points: 
  • MarketMan , a comprehensive SaaS food service inventory and purchasing platform, today announced the launch of its next-generation premium features utilizing predictive analytics that provide restaurants with automated management of their cost of goods.
  • “Predictive analytics is one of the many innovative technology advances available to run a foodservice more efficiently that has not yet been widely adopted.
  • This capability allows single or multi-location restaurant business managers to clearly identify opportunities to lower COGS and become more profitable,” says Wolf.
  • For a list of MarketMan partners, please visit: https://www.marketman.com/partners/
    The new MarketMan premium features will be showcased at the 2023 National Restaurant Association Show at McCormick Place in Chicago from May 20 to 23.

Scout Bio to Present at Upcoming Gene and Cell Therapy Summit

Retrieved on: 
Friday, May 19, 2023
Cost of goods sold, Biotechnology, CMC, Gene, DVM, Society, AAV, PST, American Society of Gene and Cell Therapy, Cell, Pharmaceutical industry

PHILADELPHIA, May 19, 2023 (GLOBE NEWSWIRE) -- Scout Bio , a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that executive officers Mark Heffernan and Anne Traas, along with co-founder Matthew Wilson, will present at the 26th annual American Society of Gene and Cell Therapy (ASGCT) Summit in Los Angeles, California on May 20, 2023.

Key Points: 
  • PHILADELPHIA, May 19, 2023 (GLOBE NEWSWIRE) -- Scout Bio , a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that executive officers Mark Heffernan and Anne Traas, along with co-founder Matthew Wilson, will present at the 26th annual American Society of Gene and Cell Therapy (ASGCT) Summit in Los Angeles, California on May 20, 2023.
  • Scout Bio Chief Executive Officer Mark Heffernan, Ph.D., will present an Overview of Animal Health Industry Similarities and Differences from Human Health.
  • Scout Bio Chief Development Officer Anne Traas, DVM MS DACT, will discuss Disease Indications in Animal Health: One Medicine Approach to Gene Therapy.
  • Scout Bio co-founder Matt Wilson will detail CMC Strategy - Decreasing Cost of Goods for Animal Health Market.

Retractable Technologies, Inc. Reports Results For 2022

Retrieved on: 
Thursday, March 30, 2023
Medical Supplies, Health, Medical Devices, Hospitals, COVID-19, General Health, Pharmaceutical, Government, Workforce, TIA, HNA Technology Investments Holdings, NYSE, RVP, Cost of goods sold, Securities and Exchange Commission (Nigeria), Cryptocurrency, Pharmaceutical industry

Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2022.

Key Points: 
  • Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2022.
  • Our revenues for 2022 decreased 49.7% as sales to the U.S. government for COVID-19 vaccinations wound down in the first quarter of 2022, although international vaccine-related sales were significantly higher in 2022.
  • Net income was $5.1 million in 2022 as compared to $56.1 million in 2021 and basic earnings per share were $0.15 in 2022 as compared to $1.65 per share in 2021.
  • Throughout 2022, reimbursements from the U.S. government under the 2020 Technology Investment Agreement (“TIA”) continued, enabling significant expansions to our facilities and equipment.

Creatd, Inc. Announces Record Preliminary Gross Revenues for FY 2022

Retrieved on: 
Monday, February 6, 2023
Corporate title, CFO, Private sector, Human voice, Dune, Frommer, National Geographic, Yoy, Acquisition, General Administration of Press and Publication, The Times, CRTD, Web 3.0, Urban Outfitters, Credit Suisse, Absorption, Cost of goods sold, WW International, Collection, Growth, CIO, IOS, Gopuff, Credit Suisse First Boston, OTCQB, OTC, Android, Video game, Music, Security (finance), Upstream, Amazon

Creatd's 2022 gross revenues totaled $10MM, a 40% increase YoY, while facing the most significant headwinds in Company's history.

Key Points: 
  • Creatd's 2022 gross revenues totaled $10MM, a 40% increase YoY, while facing the most significant headwinds in Company's history.
  • NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Creatd, Inc. (OTCQB: CRTD) ("Creatd" or the "Company"), a creator-first technology company, today announced the preliminary results for fiscal year 2022.
  • The Company's preliminary results for fiscal year 2022 include expected net revenues of nearly $5 million, and gross revenues totaling approximately $10 million, in line with previous guidance.
  • Similarly to the OG Collection, Inc. spin-off, Creatd Ventures will only be spun-off to shareholders as of a to-be-announced record date.

TradeTech's PCI Shows Uranium Production Cost Increases Due to Inflation

Retrieved on: 
Wednesday, October 5, 2022
Risk, FAM, Perception, Trade Finance Technology (TradeTech), Industry, US, Area studies, Economics, PCI, Cost of goods sold, Exchange Value, Uranium, NMR, Renewable energy, Indicator

ENGLEWOOD, Colo., Oct. 4, 2022 /PRNewswire-PRWeb/ -- TradeTech's monthly Production Cost Indicator™ (PCI) value, which captures the company's proprietary judgment of the life-of-mine full cost (LoM C3 ™) necessary to incentive and support new primary uranium production, increased 6.6 percent (US$3.50) in September to $56.20 per pound U3O8, marking 16 months without decline and the highest value since the Indicator's inception in April 2020.

Key Points: 
  • While FAM 1 production costs are typically consistent with good project development, FAM 2 reflects a cost profile associated with greater susceptibility to risk.
  • Identification of cost-related risk, such as inflation, means that projects have a greater propensity to produce uranium concentrates toward the upper levels of TradeTech's maximum conceivable production cost assumptions.
  • "TradeTech's perception of risk specific to each uranium project, including considerations of how risk translates toand impactsmining and production economics is particularly relevant to the company's assessment of uranium production costs.
  • The company's "Nuclear Market Review" (NMR) is published each Friday evening, and reports the Weekly Uranium Spot Price Indicator, uranium trading activity, industry news, and market data.

Global Automotive 3D Printing Market (2022 to 2027) - Untapped Adjacent Markets for 3D Printing Applications Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
Other Automotive, Automotive Manufacturing, Manufacturing, Automotive, Software, Technology, 3D, Cost of goods sold, DDM, Original equipment manufacturer, R, USD, Desktop Metal, Health, 3D Systems, Investment, CAGR, Printing, Growth, Industry, Life, Adoption, Development, Efficiency, 3D printing, Stratasys

3D printing in the automotive sector helps OEMs reduce cost and produce cost-effective auto parts in reduced production time.

Key Points: 
  • 3D printing in the automotive sector helps OEMs reduce cost and produce cost-effective auto parts in reduced production time.
  • Companies are investing heavily in R&D, which would supplement the growth of the 3D printing market.
  • A key factor restricting the adoption of 3D printing is the high cost associated with 3D printing materials; the cost of 3D printing materials is generally higher than bulk resin or powder counterparts.
  • Additionally, the advent of autonomous cars and development of an electric transportation system for buses and trucks would drive the European automotive 3D printing market.

Radius Health Expands Non-US Market Footprint for TYMLOS

Retrieved on: 
Wednesday, June 8, 2022
Woman, Osteoporosis, Marketing, Man, Food, Annual report, SVP, Partnership, Security (finance), Radius, U.S. Securities and Exchange Commission, COGS, Fracture, Abaloparatide, Male, GLOBE, Patient, Private Securities Litigation Reform Act, Risk, RAD1901, Media relations, Cost of goods sold, COVID-19, Bone fracture, NASDAQ, SEC, Cost, History, Regulation of tobacco by the U.S. Food and Drug Administration, Real estate, Fine chemical, Dietary supplement, Public relations, Pharmaceutical industry, EU

Three additional market agreements now signed and executed:

Key Points: 
  • Three additional market agreements now signed and executed:
    BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection.
  • In accordance with the terms of the agreements, each company will register, commercialize, and distribute TYMLOS on an exclusive basis in their respective territories.
  • These counterparties will be responsible for all commercial activities related to TYMLOS including sales, marketing, medical affairs, pricing, and reimbursement.
  • Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan neurosciences diseases, and oncology.